Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty

Circulation

Volumn 107, Issue 14, 2003, Pages 1840-1843

  Wöhrle, Jochen ^b   Grebe, Olaf C ^b   Nusser, Thorsten ^b   Al Khayer, Eyas ^b   Schaible, Stefan ^b   Kochs, Matthias ^b   Hombach, Vinzenz ^b   Höher, Martin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b NONE

Author keywords

Angioplasty; Glycoproteins; Myocardial infarction; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BOLUS INJECTION; CARDIOGENIC SHOCK; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; HEART; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 0344519722     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000066852.98038.D1     Document Type: Article

References (9)

1. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoproteinIIb/IIIa blockadei the EPISTENT investigators. Evaluation of Platelet IIb/IIIa inhibitor for stenting. Lancet. 1998;352:87-92.
2. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med, 2002;346:957-966.
3. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
4. Thuraisingham S, Tan KH. Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab. Int J Clin Pract. 1999;53:604-607.
5. Bailey SR, O'Leary E, Chilton R. Angioscopic evaluation of site-specific administration of ReoPro. Cathet Cardiovasc Diagn. 1997;42:181-184.
6. Barsness GW, Buller C, Ohman EM, et al. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts. Am Heart J. 2000;139:824-829.
7. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-1924.
8. Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platetet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535.
9. Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention. Circulation. 2002;105: 2730-2736.